<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33767237</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>25</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>6849</StartPage><MedlinePgn>6849</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6849</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-86211-4</ELocationID><Abstract><AbstractText>This study aimed to investigate four of the eight PFN-1 mutations that are located near the actin-binding domain and determine the structural changes due to each mutant and unravel how these mutations alter protein structural behavior. Swapaa's command in UCSF chimera for generating mutations, FTMAP were employed and the data was analyzed by RMSD, RMSF graphs, Rg, hydrogen bonding analysis, and RRdisMaps utilizing Autodock4 and GROMACS. The functional changes and virtual screening, structural dynamics, and chemical bonding behavior changes, molecular docking simulation with two current FDA-approved drugs for ALS were investigated. The highest reduction and increase in Rg were found to exist in the G117V and M113T mutants, respectively. The RMSF data consistently shows changes nearby to this site. The in silico data described indicate that each of the mutations is capable of altering the structure of PFN-1 in vivo. The potential effect of riluzole and edaravone two FDA approved drugs for ALS, impacting the structural deviations and stabilization of the mutant PFN-1 is evaluated using in silico tools. Overall, the analysis of data collected reveals structural changes of mutant PFN-1 protein that may explain the neurotoxicity and the reason(s) for possible loss and gain of function of PFN-1 in the neurotoxic model of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sadr</LastName><ForeName>Ahmad Shahir</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Computer and Data Sciences, Faculty of Mathematical Sciences, Shahid Beheshti University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eslahchi</LastName><ForeName>Changiz</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Computer and Data Sciences, Faculty of Mathematical Sciences, Shahid Beheshti University, Tehran, Iran. ch-eslahchi@sbu.ac.ir.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biological Sciences, Institute for Research in Fundamental Sciences (IPM), 193955746, Tehran, Iran. ch-eslahchi@sbu.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghassempour</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiaei</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA. mkiaei@uams.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA. mkiaei@uams.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatrics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA. mkiaei@uams.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>RockGen Therapeutics, LLC., c/o Bioventures, LLC, 4301 W. Markham St., #831, Little Rock, AR, 72205, USA. mkiaei@uams.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495738">PFN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051304">Profilins</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="Y">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051304" MajorTopicYN="N">Profilins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>M.K. is the founder, president, and CEO of RockGen Therapeutics, LLC.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33767237</ArticleId><ArticleId IdType="pmc">PMC7994392</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-86211-4</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-86211-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Longo, D.L. Robert H. Brown, D. Phil., MD, and Ammar AlChalabi, Ph. D., FRCP, Dip. Stat. N. Engl. J. Med.377, 162&#x2013;172 (2017).</Citation></Reference><Reference><Citation>Dervishi I, Ozdinler PH. Incorporating upper motor neuron health in ALS drug discovery. Drug Discov. Today. 2018;23(3):696&#x2013;703. doi: 10.1016/j.drudis.2018.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2018.01.027</ArticleId><ArticleId IdType="pmc">PMC5849515</ArticleId><ArticleId IdType="pubmed">29331501</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HP, Van Broeckhoven C, van der Zee J. ALS genes in the genomic era and their implications for FTD. Trends Genet. 2018;34(6):404&#x2013;423. doi: 10.1016/j.tig.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2018.03.001</ArticleId><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C-H, Fallini C, Ticozzi N, Keagle PJ, Sapp PC, Piotrowska K, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488(7412):499&#x2013;503. doi: 10.1038/nature11280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11280</ArticleId><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkam D, Feldman EZ, Singh A, Kiaei M. Profilin1 biology and its mutation, actin (g) in disease. Cell. Mol. Life Sci. 2017;74(6):967&#x2013;981. doi: 10.1007/s00018-016-2372-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2372-1</ArticleId><ArticleId IdType="pmc">PMC5311022</ArticleId><ArticleId IdType="pubmed">27669692</ArticleId></ArticleIdList></Reference><Reference><Citation>Gau D, Veon W, Shroff SG, Roy P. The VASP&#x2013;profilin1 (Pfn1) interaction is critical for efficient cell migration and is regulated by cell&#x2013;substrate adhesion in a PKA-dependent manner. J. Biol. Chem. 2019;294(17):6972&#x2013;6985. doi: 10.1074/jbc.RA118.005255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.005255</ArticleId><ArticleId IdType="pmc">PMC6497960</ArticleId><ArticleId IdType="pubmed">30814249</ArticleId></ArticleIdList></Reference><Reference><Citation>Potapov V, Cohen M, Schreiber G. Assessing computational methods for predicting protein stability upon mutation: good on average but not in the details. Protein Eng. Des. Sel. 2009;22(9):553&#x2013;560. doi: 10.1093/protein/gzp030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/protein/gzp030</ArticleId><ArticleId IdType="pubmed">19561092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodos RA, Kidd BA, Shameer K, Readhead BP, Dudley JT. In silico methods for drug repurposing and pharmacology. Wiley Interdiscip. Rev. Syst. Biol. Med. 2016;8(3):186&#x2013;210. doi: 10.1002/wsbm.1337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wsbm.1337</ArticleId><ArticleId IdType="pmc">PMC4845762</ArticleId><ArticleId IdType="pubmed">27080087</ArticleId></ArticleIdList></Reference><Reference><Citation>Ideker T, Galitski T, Hood L. A new approach to decoding life: Systems biology. Annu. Rev. Genom. Hum. Genet. 2001;2(1):343&#x2013;372. doi: 10.1146/annurev.genom.2.1.343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.genom.2.1.343</ArticleId><ArticleId IdType="pubmed">11701654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschner MW. The meaning of systems biology. Cell. 2005;121(4):503&#x2013;504. doi: 10.1016/j.cell.2005.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.05.005</ArticleId><ArticleId IdType="pubmed">15907462</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble D. Claude Bernard, the first systems biologist, and the future of physiology. Exp. Physiol. 2008;93(1):16&#x2013;26. doi: 10.1113/expphysiol.2007.038695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/expphysiol.2007.038695</ArticleId><ArticleId IdType="pubmed">17951329</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera&#x2014;A visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25(13):1605&#x2013;1612. doi: 10.1002/jcc.20084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20084</ArticleId><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava A, Nagai T, Srivastava A, Miyashita O, Tama F. Role of computational methods in going beyond X-ray crystallography to explore protein structure and dynamics. Int. J. Mol. Sci. 2018;19(11):3401. doi: 10.3390/ijms19113401.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19113401</ArticleId><ArticleId IdType="pmc">PMC6274748</ArticleId><ArticleId IdType="pubmed">30380757</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham, M., van der Spoel, D., Lindahl, E., Hess, B. GROMACS user manual version 2018. www.gromacs.org (2018).</Citation></Reference><Reference><Citation>Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: Fast, flexible, and free. J. Comput. Chem. 2005;26(16):1701&#x2013;1718. doi: 10.1002/jcc.20291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20291</ArticleId><ArticleId IdType="pubmed">16211538</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemkul J. From proteins to perturbed Hamiltonians: A suite of tutorials for the GROMACS-2018 molecular simulation package [article v1.0] Living J. Comput. Mol. Sci. 2018;1(1):5068.</Citation></Reference><Reference><Citation>Turner, P., Stambulchik, E., Unix-Like, A. Grace (plotting tool). (2012).</Citation></Reference><Reference><Citation>Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2019 update: Improved access to chemical data. Nucleic Acids Res. 2019;47(D1):D1102&#x2013;D1109. doi: 10.1093/nar/gky1033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1033</ArticleId><ArticleId IdType="pmc">PMC6324075</ArticleId><ArticleId IdType="pubmed">30371825</ArticleId></ArticleIdList></Reference><Reference><Citation>GaussView V. 4.1, Roy Dennington II, Todd Keith and John Millam, Semichem. Inc, Shawnee Mission, KS. (2007).</Citation></Reference><Reference><Citation>Frisch, M. Gaussian 03 Rev. E. 01. http://www.gaussian.com/. (2004).</Citation></Reference><Reference><Citation>Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30(16):2785&#x2013;2791. doi: 10.1002/jcc.21256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.21256</ArticleId><ArticleId IdType="pmc">PMC2760638</ArticleId><ArticleId IdType="pubmed">19399780</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng. Des. Sel. 1995;8(2):127&#x2013;134. doi: 10.1093/protein/8.2.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/protein/8.2.127</ArticleId><ArticleId IdType="pubmed">7630882</ArticleId></ArticleIdList></Reference><Reference><Citation>Nekouei M, Ghezellou P, Aliahmadi A, Arjmand S, Kiaei M, Ghassempour A. Changes in biophysical characteristics of PFN1 due to mutation causing amyotrophic lateral sclerosis. Metab. Brain Dis. 2018;33(6):1975&#x2013;1984. doi: 10.1007/s11011-018-0305-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-018-0305-4</ArticleId><ArticleId IdType="pmc">PMC6230493</ArticleId><ArticleId IdType="pubmed">30203378</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front. Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Jubb HC, Pandurangan AP, Turner MA, Ochoa-Monta&#xf1;o B, Blundell TL, Ascher DB. Mutations at protein&#x2013;protein interfaces: Small changes over big surfaces have large impacts on human health. Prog. Biophys. Mol. Biol. 2017;128:3&#x2013;13. doi: 10.1016/j.pbiomolbio.2016.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbiomolbio.2016.10.002</ArticleId><ArticleId IdType="pubmed">27913149</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiorov VN, Crippen GM. Significance of root-mean-square deviation in comparing three-dimensional structures of globular proteins. J. Mol. Biol. 1994;235:625&#x2013;634. doi: 10.1006/jmbi.1994.1017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.1994.1017</ArticleId><ArticleId IdType="pubmed">8289285</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazals F, Tetley R. Characterizing molecular flexibility by combining least root mean square deviation measures. Proteins Struct. Funct. Bioinform. 2019;87(5):380&#x2013;389. doi: 10.1002/prot.25658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.25658</ArticleId><ArticleId IdType="pubmed">30663799</ArticleId></ArticleIdList></Reference><Reference><Citation>Low B-C. Root mean square fluctuation of a weak magnetic field in an infinite medium of homogeneous stationary turbulence. Astrophys. J. 1972;173:549. doi: 10.1086/151443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/151443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kufareva I, Abagyan R. Methods of Protein Structure Comparison. Springer; 2011. pp. 231&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4321859</ArticleId><ArticleId IdType="pubmed">22323224</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobanov MY, Bogatyreva N, Galzitskaya O. Radius of gyration as an indicator of protein structure compactness. Mol. Biol. 2008;42(4):623&#x2013;628. doi: 10.1134/S0026893308040195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0026893308040195</ArticleId></ArticleIdList></Reference><Reference><Citation>Berjanskii M, Wishart DS. NMR: Prediction of protein flexibility. Nat. Protoc. 2006;1(2):683. doi: 10.1038/nprot.2006.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.108</ArticleId><ArticleId IdType="pubmed">17406296</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng EC, et al. Tools for integrated sequence-structure analysis with UCSF Chimera. BMC Bioinform. 2006;7(1):1&#x2013;10. doi: 10.1186/1471-2105-7-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-7-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JE, Huang CC, Ferrin TE. RRDistMaps: A UCSF Chimera tool for viewing and comparing protein distance maps. Bioinformatics. 2015;31(9):1484&#x2013;1486. doi: 10.1093/bioinformatics/btu841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu841</ArticleId><ArticleId IdType="pmc">PMC4410660</ArticleId><ArticleId IdType="pubmed">25540183</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngan CH, Bohnuud T, Mottarella SE, Beglov D, Villar EA, Hall DR, et al. FTMAP: Extended protein mapping with user-selected probe molecules. Nucleic Acids Res. 2012;40(W1):W271&#x2013;W275. doi: 10.1093/nar/gks441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks441</ArticleId><ArticleId IdType="pmc">PMC3394268</ArticleId><ArticleId IdType="pubmed">22589414</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira GRC, Tellini GHAS, De Mesquita JF. In silico analysis of PFN1 related to amyotrophic lateral sclerosis. PLoS ONE. 2019;14(6):e0215723. doi: 10.1371/journal.pone.0215723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0215723</ArticleId><ArticleId IdType="pmc">PMC6583998</ArticleId><ArticleId IdType="pubmed">31216283</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>